He is a graduate of Leeds University, UK (Pharmacology and Microbiology BSc, Joint Honors) and obtained his PhD from the University of London (Institute and Cancer Research, Royal Marsden Hospital, London UK). Dr. Graham has extensive R&D experience with both small molecules and protein therapeutics from IND to NDA/BLA and has been involved in numerous regulatory filings and product approvals in both the US, Japan and Europe for a wide variety of drugs including Oxaliplatin, Remicade, Stelara, Rasburicase, Mitoguazone, Tirapazamine, and Alfuzosin.